Osteoporosis Clinical Trial
— STRONGEROfficial title:
Assessment of Cortical Bone Mechanics Technology (CBMT) Fracture Discrimination Capability
NCT number | NCT05721898 |
Other study ID # | 21-F-1 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 1, 2022 |
Est. completion date | October 30, 2023 |
Verified date | October 2023 |
Source | Ohio University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue leading to bone fragility (i.e., weakness) and an increased risk for fracture. Bone strength is a critical factor in a bone's ability to resist fracture and is clearly an important outcome in studies of osteoporosis. The current standard for assessing bone health and diagnosing osteoporosis is to use dual-energy x-ray absorptiometry (DXA) to quantify the areal bone mineral density (BMD), typically at the hip and spine. However, DXA-derived BMD has limited discriminatory accuracy for distinguishing individuals that experience fragility fracture from those who do not. One well known limitation of DXA-derived BMD is that it does not adequately assay bone strength. There is a critical unmet need to identify persons more accurately with diminished bone strength who are at high risk of experiencing a fragility fracture in order to determine an appropriate therapy. A potential new diagnostic approach to assess skeletal health and improve osteoporosis diagnosis is the use of Cortical Bone Mechanics Technology (CBMT). CBMT leverages multifrequency vibration analysis to conduct a noninvasive, dynamic 3-point bending test that makes direct, mechanical measurements of ulnar cortical bone. Data indicates that CBMT-derived ulnar flexural rigidity accurately estimates ulnar whole bone strength and provides information about cortical bone that is unique and independent of DXA-derived BMD. However, the clinical utility of CBMT-derived flexural rigidity has not yet been demonstrated. The investigators have designed a clinical study to assess the accuracy of CBMT-derived ulnar flexural rigidity in discriminating post-menopausal women who have suffered a fragility fracture from those who have not. These data will be compared to DXA-derived peripheral and central measures of BMD obtained from the same subjects.
Status | Completed |
Enrollment | 394 |
Est. completion date | October 30, 2023 |
Est. primary completion date | October 30, 2023 |
Accepts healthy volunteers | |
Gender | Female |
Age group | 50 Years to 80 Years |
Eligibility | Inclusion and Exclusion Criteria for Subjects Who Have Experienced a Fragility Fracture (Cases) Inclusion Criteria - Female. - Age range: 50 to 80 years at recruitment. All subjects must self-report that their last menses occurred at least 24-months prior to enrollment. - Has experienced a fragility fracture of the arms (including wrist fractures) or legs (including hip, pelvis, or ankle fractures) after the age of 50 years. Fractures of the spine, digits, toes or face will not be considered. A fragility fracture is operationally define based on self-report of an arm or leg fracture caused by falls from a height <6 inches. A fragility fracture will not count if it is associated with 1) running, bicycling or other similar fast-moving activity such as sports subjects, 2) being struck by a falling or otherwise quickly moving heavy object, or 3) a motor vehicle accident. Insufficiency/stress fractures will not be included. - Body mass index between 18.5 and 35 kg/m2. - Physically able to safely participate in the study activities. - Able to provide informed consent. Exclusion Criteria - Failure to provide informed consent. - Has had bilateral hip replacements. - Lives in a nursing home; persons living in assisted or independent housing will not be excluded. - Self-reported type 1 diabetes. - Unable to communicate because of severe hearing loss or speech disorder. - Self-reports being told by a physician that they have a terminal illness. - The subject will be excluded if they answer yes to the following question: Do you have an active rotator cuff tear, had shoulder surgery in the past 12-months, or experience severe shoulder, wrist, or elbow joint pain on a regular basis? - Use of systemic glucocorticoids for more than 6-months in the prior one year. - Self-reported diseases that could interfere with bone metabolism. For example, osteomalacia, bone cancer, myeloma, Pagets disease, hyper parathyroidism, hyperthyroidism not treated, severe renal (stage 4+ chronic kidney disease, history of dialysis, kidney transplant, etc.) or hepatic insufficiency, prolonged immobilization (more than 2 months in the previous year). - If, in the opinion of a site PI, the subject is inappropriate for the scientific purposes of this study. For instance, a high fall risk patient due to an existing neurological disorder (e.g., Parkinsons disease, ALS, etc.) would be excluded. Inclusion and Exclusion Criteria for Subjects Who Have Not Experienced a Fragility Fracture (Controls) Inclusion Criteria - Female. - Age range: 50 to 80 years at recruitment. All subjects must self-report that their last menses occurred at least 24-months prior to enrollment. - Self-reports not experiencing a fracture at any site after the age of 40 years (does not include fractures of the digits, toes or face). - Does not self-report losing more than 1.5 inches in stature (height) in the previous 15 years. - Body mass index between 18.5 and 35 kg/m2. - Physically able to safely participate in the study activities. - Able to provide informed consent. Exclusion Criteria - Failure to provide informed consent. - Has had bilateral hip replacements. - Lives in a nursing home; persons living in assisted or independent housing will not be excluded. - Self-reported type 1 diabetes. - Unable to communicate because of severe hearing loss or speech disorder. - Self-reports being told by a physician that they have a terminal illness. - The subject will be excluded if they answer yes to the following question: Do you have an active rotator cuff tear, had shoulder surgery in the past 12-months, or experience severe shoulder, wrist, or elbow joint pain on a regular basis? - Use of systemic glucocorticoids for more than 6-months in the prior one year. - Self-reported diseases that could interfere with bone metabolism. For example, osteomalacia, bone cancer, myeloma, Pagets disease, hyper parathyroidism, hyperthyroidism not treated, severe renal (stage 4+ chronic kidney disease, history of dialysis, kidney transplant, etc.) or hepatic insufficiency, prolonged immobilization (more than 2 months in the previous year). - If, in the opinion of a site PI, the subject is inappropriate for the scientific purposes of this study. For instance, a high fall risk patient due to an existing neurological disorder (e.g., Parkinsons disease, ALS, etc.) would be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | Ohio Musculoskeletal and Neurological Institute at Ohio University | Athens | Ohio |
United States | University of Florida | Gainesville | Florida |
United States | Indiana Center for Musculoskeletal Health | Indianapolis | Indiana |
United States | University of Florida | Jacksonville | Florida |
United States | University of South Florida | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Ohio University | Indiana University School of Medicine, University of Florida, University of South Florida |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Discriminatory Accuracy of CBMT vs. BMD | Discriminatory accuracy of ulnar flexural rigidity in comparison to the bone mineral density. | 1 Day | |
Primary | CBMT's Added Value | Binomial logistic regression's Walt coefficient to quantify how ulnar flexural rigidity and areal BMD predicts group membership (cases and controls). | 1 Day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06287502 -
Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis
|
N/A | |
Completed |
NCT03822078 -
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
|
Phase 1 | |
Recruiting |
NCT05845021 -
Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04736693 -
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
|
||
Not yet recruiting |
NCT06431867 -
Primary Care Management of Osteoporosis in Older Women
|
||
Completed |
NCT02922478 -
Role of Comorbidities in Chronic Heart Failure Study
|
||
Recruiting |
NCT02616627 -
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
|
||
Recruiting |
NCT02635022 -
Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
|
||
Active, not recruiting |
NCT02617303 -
Prevention of Falls and Its Consequences in Elderly People
|
N/A | |
Completed |
NCT02566655 -
Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis
|
Phase 1 | |
Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
Not yet recruiting |
NCT02223572 -
Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
|
N/A | |
Completed |
NCT03420716 -
Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women
|
N/A | |
Not yet recruiting |
NCT01854086 -
Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday
|
N/A | |
Completed |
NCT02003716 -
DeFRA Questionnaire as an Anamnestic Form
|
N/A | |
Unknown status |
NCT01913834 -
Nasally and sc Administered Teriparatide in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01694784 -
Understanding and Discouraging Overuse of Potentially Harmful Screening Tests
|
N/A | |
Completed |
NCT01401556 -
C-STOP Fracture Trial
|
N/A |